Loading...
XMAD
PRM
Market cap259mUSD
Jul 09, Last price  
13.35EUR
1D
-0.37%
1Q
0.38%
Jan 2017
50.00%
Name

Prim SA

Chart & Performance

D1W1MN
XMAD:PRM chart
P/E
13.61
P/S
0.90
EPS
0.98
Div Yield, %
3.33%
Shrs. gr., 5y
150.28%
Rev. gr., 5y
11.32%
Revenues
252m
+8.01%
90,542,00091,630,00095,761,00095,497,00095,112,00091,446,00088,662,00087,000,00094,206,00099,228,000110,100,000121,273,000134,430,000150,999,000147,324,000168,512,000197,245,000216,511,000233,147,000251,816,000
Net income
17m
+52.77%
7,555,00010,060,0009,904,00010,035,0008,532,0008,909,0009,135,0009,634,0009,962,00010,703,00013,097,00013,898,00014,119,00011,218,0006,917,00017,423,0008,391,00012,673,00010,920,00016,683,000
CFO
30m
+37.81%
7,054,96211,700,92007,212,7970045,311,4394,999,05923,184,29512,245,80611,596,29512,438,4136,574,479652,23724,977,71524,497,5824,889,666022,105,00030,463,000
Dividend
Dec 19, 20250.1053 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassotherapy and hydrotherapy), rehabilitation, spa facilities, elderly care, and a range of supportive techniques, reaching customers within Spain and across global borders. Furthermore, the company supplies specialized goods for neuro-trauma, cardiovascular health, neuromodulation, surgical suites, endosurgical procedures, cosmetic surgery, and ear, nose, and throat (ENT) specialties. Beyond its product offerings, Prim, S.A. is involved in overseeing wellness developments, including hotel properties, vacation resorts, and athletic clubs. The firm was established in 1870 and maintains its principal office in Móstoles, Spain.
IPO date
Jan 21, 1997
Employees
827
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT